Offer - Urjas Oil for just ₹ 1 X
Cadrubin is a prescription drug, available for use as Injection. Primarily, it is used for the treatment of Breast Cancer.
The correct dosage of Cadrubin depends on the patient's age, gender, and medical history. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. For detailed information on this, read through the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Cadrubin as well, which are listed below. Normally, these side effects of Cadrubin are not long lasting and go away when the treatment is finished. Please speak with your doctor if these side effects worsen or persist for a longer duration.
It is also important to note that Cadrubin has a Severe effect for pregnant women and Severe effect on lactating mothers. Warnings related to Cadrubin's effects on the liver, heart and kidney, if any, have been listed below.
Other contraindications of Cadrubin have been discussed in the sections ahead.
Drug interactions for Cadrubin have been reported in the medical literature. See below for a complete list.
In addition to the above precautions for Cadrubin, it is important to know that it is not safe while driving, and is not habit-forming.
Cadrubin is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult(Female) |
|
Geriatric |
|
Is the use of Cadrubin safe for pregnant women?
Cadrubin should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Cadrubin safe during breastfeeding?
Women who are breastfeeding, may experience serious side effects after taking Cadrubin. So it is adviced to consult the doctor before using it.
What is the effect of Cadrubin on the Kidneys?
There may be some adverse effects on kidney after taking Cadrubin. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Cadrubin on the Liver?
There may be an adverse effect on the liver after taking Cadrubin. If you observe any side effects on your body then stop taking this drug. Take this medicine again only if your doctor advises you to do so.
What is the effect of Cadrubin on the Heart?
The heart can be affected by Cadrubin. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart the medicine only after medical advice.
Cadrubin should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
If you are suffering from any of the following diseases, you should not take Cadrubin unless your doctor advises you to do so -
Is this Cadrubin habit forming or addictive?
No, there is no any evidence that Cadrubin is addictive.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Cadrubin. So it is best to avoid driving.
Is it safe?
Cadrubin should be used only after doctor's advice.
Is it able to treat mental disorders?
Cadrubin is unable to treat or cure mental disorders.
Interaction between Food and Cadrubin
It is safe to take Cadrubin with food.
Interaction between Alcohol and Cadrubin
Consuming Cadrubin with alcohol can have many serious effects on your body.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Ellence® (epirubicin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 867
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 505-508